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Background: Breast cancer (BC) is a genetic disorder characterized by growth and proliferation of breast cells in a
disorderly. In Brazil, there are approximately 49.240 new cases of BC, every year. The BC etiology is still poorly
understood. The BC can be sporadic (SBC) or hereditary (HBC). Recent studies have correlated gene polymorphisms
with the BC, such as alterations in thymidylate synthase gene (TYMS), which are used to improve diagnosis and
prevention of the disease. Polymorphisms in the TYMS gene 5’-UTR region, usually present reps double (2R) and/or
triple (3R). Studies have shown that homozygous 3R/3R is overexpressed compared with 2R/2R genotype, and
these polymorphic variations may contribute to individual susceptibility to the development of BC. In this context,
the objective of this study was to evaluate the frequency of the TYMS 2R and 3R polymorphisms, comparing
genotypic and allelic distribution with SBC and HBC patients.
Methods: In this study we included a total of 204 subjects, 70 with BC (33 with SBC, and 37 with HBC) and 134
healthy subjects (controls). The Polymerase Chain Reaction was the method used.
Results: Results demonstrated a high frequency of the 3R allele at BC, SBC, and HBC groups. The frequency of
genotype 2R/3R was significantly higher in BC group. This work showed association between the 2R/3R variants
(OR = 4.14, CI95% = 1.77-9.71) in the development of SBC, and 2R/2R (OR = 0.233, CI95% = 1.63-7.65) and 2R/3R
(OR = 3.53, CI95% = 0.06-0.81) for developing HBC. To BC, there was association with the genotype 2R/3R (OR: 3.79,
CI95% = 2.03-7.08).
Conclusion: Our results show relation to the development of BC in association with the analyzed polymorphisms.
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Hereditary breast cancerBackground
Breast cancer (BC) is a genetic disease characterized by
an out of control growing breast cells, resulting in cellu-
lar proliferation, invasion of surrounding tissues and
other organs, with possibility of metastasis [1]. BC is the
second leading cancer in the population, it is the most
common cancer among women, and the second leading* Correspondence: fernandolimamarson@hotmail.com
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reproduction in any medium, provided the orcause of death within them, with approximately 460.000
deaths/year worldwide [1,2].
In recent years risk factors for BC have been identified,
although the etiology of the disease is still not under-
stood. Risk factors that contribute to the development of
BC include age, ethnicity, reproduction, some kind of
hormones, lifestyle, bone density, genetic factors [3] and
family history [4]. The majority of hereditary breast can-
cer (HBC) susceptibility can be attributed to germline
mutations of to Breast Cancer 1 and Breast Cancer 2
genes (BRCA1 and BRCA2), which are responsible for
30-40% of HBC. Clinically, the basis of HBC is estab-
lished at an early age, family history, bilateral BC, maletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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compared to the sporadic form [5].
Most of BC are sporadic (SBC), resulting from gene
mutations, uncorrected, located in somatic cells, and un-
related to germline mutation. Risk factors for SBC are
often hormonal [6], although, it may be related to other
risk factors like smoking, ionizing radiation and geno-
toxics agents [7].
Recently, the association of polymorphisms in some
genes has been demonstrated as a possible etiologic
factor of neoplasia and response to chemotherapy [8].
Molecular markers related to BC have been described
as risk factors, being studied as a biomarker of diagno-
sis, prognosis and prevention [3,9]. Among them, the
Thymidylate synthase gene (TYMS), located at band
18p11.32 has been studied [9]. Thymidylate synthase is a
key enzyme in the folate metabolism originating from the
diet, catalyzing the deoxyuridine monophosphate conver-
sion for deoxythymidine monophosphate process of DNA
synthesis. The conversion is essential for the production
of thymidine, nucleotide required for DNA repair and syn-
thesis [3].
In humans the TYMS gene is widely polymorphic, and
variable number of tandem repetitions (VNRT) are found
in the promoter enhancer region five primer - untranslated
region (5’-UTR), in most cases, with two (2R) or three
repetitions (3R) of a sequence of 28 bp [9]. Studies have
shown that the homozygotes 3R/3R increase expression of
TYMS mRNA when compared to cells in 2R/2R homozy-
gotes [3,10,11]. In addition to these alleles, other rarer may
have SNPs of 3R alleles, and other VNRTs [10,12,13].
Polymorphisms in TYMS gene may have effects on the
stability of RNAm, and thus, affecting the translation
level of the protein expression. These genotypic effects
may contribute to individual susceptibility to BC [11,12],
and have been related to pharmacogenetic variation in
chemotherapy treatments [14,15].
Based on the few reports, our objective was to evaluate
the frequency of polymorphisms of the promoter region
enhancer 5’-UTR of the TYMS gene (2R and 3R), com-
paring the results between HBC and SBC patients. As
the polymorphism acts in the cycle of folic acid, it may
be involved in the etiology of both the second mutation
hereditary cases, as in mutations in sporadic cases.
Methods
The present study was developed in a total of 70 Caucasian
individuals into two distinct groups (I) 33 patients with
SBC (without family history), and (II) 37 patients with
HBC (with family history), to from the metropolitan region
of Campinas, which take the treatment at the Clinical
Hospital of UNICAMP. The control group was compound
by 134 healthy subjects (only females) without history of
BC, ovarian or prostate cancer in the family [16], and anormal population without taking into account the BC his-
tory composed by 67 males and 67 females recruited in
hospital hemocenter, to evaluated the Hardy-Weinberg
equilibrium in a normal population.
The patients group was analyzed consecutively in our
study. To be include in the HBC group the patient should
have the following: (i) to have breast cancer below 35 years
old and bilaterality; (ii) or, familiar with breast and/or
ovarian cancer, one of whom diagnosed at the age below of
60 years old, or bilateral breast cancer; (iii) or, two or more
cases of breast or ovarian cancer in the 1st degree relatives,
independently of presentation age of the neoplasia; (iv) or,
two 1st degree relatives with breast cancer, one diagnosed
age below 45 years old; (v) or, two 1st degree relatives with
ovarian cancer; (vi) male relative with breast cancer, with-
out taking age into account. To be including in the SBC
group the patient should have the breast cancer, in other
conditions as HBC (based on www.spsenologia.pt). The
control group should have three characteristic: (i) no breast
cancer diagnosed; (ii) no familiar historical to breast, ova-
rian or prostate cancer; (iii) the same age than case group
(based on www.spsenologia.pt).
The patients and control group were matched by age.
All patients and controls included were Caucasian
woman to statistical analysis.
The study was approved by the Ethics Committee of the
Medical Sciences Faculty of UNICAMP (CEP: N°913/2011,
CAAE: 0812.0.146.000-11) and it was developed with
biological material stored in the DNA Bank stored at the
Laboratory of Molecular Genetics (Department of Medical
Genetics, School of Medical Sciences - UNICAMP). All
patients signed a consent form before beginning the study.
Polymorphisms analysis of the promoter enhancer region
5’-UTR of the TYMS gene (2R and 3R)
The DNA was extracted by phenol-chloroform method
from peripheral venous blood. The identification of VNRT
polymorphisms of the 5’UTR region of the TYMS gene
was performed by PCR following the protocol: 12 μL of
sterile ultra-pure water; 4 μL of dNTP mix (1.25 mM
each) (Life Technologies, Waltham, MA, United States of
America); 0.3 μL of Taq DNA polymerase (5 U) (Life
Technologies, Waltham, MA, United States of America);
2.5 μL of 10x PCR assay buffer (500 mM Tris pH9.0,
200 mM NH4SO4, 15 mM MgCl2); 4 μL of MgCl2
(50 mM); 1 μL of primer (20 pmol) (Biotech) TYMS-F
(Forward: 5’–GTGGCTCCTGCGTTTCCCCC–3’) and
1 μL of TYMS-R (Reverse: 5’– CCAAGCTTGGCTCCGA
GCCGGCCACAGGCATGGCGCGG–3’) [8]; resulting a
final amount of 50 μL. The reaction was subjected to an
initial denaturation step at 94.0°C for 5 minutes, followed
by 35 cycles of denaturation at 94.0°C for 1 minute,
annealing of primers (at 59.1°C for 1 minute, and exten-
sion at 72.0°C for 2 minutes, and 10 minutes of final
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loped in a 12% polyacrylamide gel electrophoresis.
Statistical analysis
The statistical analyze between HBC and SBC groups was
calculated using the Chi-square test Yates corrected and
the Fisher Exact test through the software Statistical
Package for Social Sciences v.17.0 (version 17, SPSS Inc.,
Chicago, IL) [17]. Associations between polymorphisms
in the 5’-UTR region of TYMS and BC risk were obtained
through the Odds Ratios (ORs) was calculated, conside-
ring a 95% confidence interval (CI) and p-values less to
0.05. Hardy-Weinberg imbalance has been evaluated for
the three groups using the program HAPLOVIEW [18].
According to G*power 3.1.2 software, to a power of
80% in the analyses, we need, respectively, 52 and 56
subjects, to Fisher Exact test and Chi-square test.
Results
A total of 204 subjects was included in this study, 70
with breast cancer (33 with SBC, and 37 with HBC), and
134 healthy subjects without family history of BC (Con-
trols). Four (04) individuals who had rare alleles (3R/4R,
in two individuals with SBC; and 2R/4R, in two control
individuals) were excluded from statistical analyses. The
SBC Group (p = 0.054) was Hardy-Weinberg (HW) equi-
librium. However, a HW imbalance was found in the
control group (p = 0.005) and HBC patients (p = 0.048).
To normal group population, the sample was not in
Hardy-Weinberg (X2 = 8.41, p < 0.005).
Polymorphisms frequencies found in tandem in the
5’UTR region (2R and 3R) of the TYMS gene are shown
in Table 1. The 3R allele had a higher frequency than
the 2R allele in individuals with cancer (SBC, HBC and
BC) and controls. Heterozygotes genotype (2R/3R) fre-
quencies were significantly higher in individuals with BC
(in both, SBC and HBC groups) than in controls.
Data (Table 2) show no significant difference between
allele frequencies (2R and 3R) found in patients with can-
cer (SBC and HBC) when compared with the controls.
The low frequency of heterozygous genotype (2R/3R) in
control individuals brought a bias, equating them to the
results found for frequency of BC patients. However,
when compared genotypic variations (2R/2R, 2R/3R andTable 1 Frequency of genotypes and alleles of the TYMS gene
Groups N Genotypic Frequencie
2R/2R 2R/3R
SBC 31 4 (13) 22 (71)
HBC 37 3 (8) 25 (68)
BC 68 7 (10) 47 (69)
Control 132 36 (27) 49 (37)
N = Number of individuals used for analysis; n = (%) Frequencies; SBC = sporadic bre3R/3R) of the TYMS gene between BC individuals and
controls, there were statistical differences (Table 3).
The genotypic comparison between SBC patients and
the controls showed a significant association with 2R/3R
genotype variants (OR = 4.14; CI95% = 1.77-9.71). Now,
when compared individuals with HBC to the controls
individuals, the association was present for the 2R/2R
genotypes (OR = 0.23; CI95% = 0.06-0.81) and 2R/3R
(OR = 3.53; CI95% = 1.63-7.65). In the comparison bet-
ween BC patients (SBC plus HBC) and controls, the
association was presented in the 2R/3R genotype in the
BC group (OR = 3.79, IC95% = 2.03-1.11). An additional
analyze was did considering the normal population versus
BC, and we observed the same corresponding association.
The 2R/3R patient had bigger OR to cancer when com-
pared with other patients (OR = 3.764; CI95% = 2.02-7.13),
considering the genotypes frequency to the normal popu-
lation, 36, 49 and 47; respectively to 2R/2R, 2R/3R and
3R/3R genotypes.
Discussion
Breast Cancer has been associated with polymorphisms
in genes candidate to be disease modifiers, such as CYP19
(Family 19 of the Cytochrome P450), GSTP1 (Glutathione
S-Transferase Protein), TP53 (Tumor Protein 53), P21
(Protein 21) [19], MTHFR (Methylenetetrahydrofolate
Reductase) and TYMS (Thymidylate Synthase) [20] and,
which are involved in events such as synthesis, methyla-
tion and DNA damage repair, and cellular activation in
carcinogen metabolism and the metabolism of anticancer
drugs. Gene variations, besides being related to risk factors
for the development of BC, they can interfere with gene
expression or activity level, and may be associated with
different tumor phenotypes tumor [21-23]. The study of
genetic variation may influence clinical management and
better pharmacogenetic intervention to BC [24,25].
In the present study it was investigated whether poly-
morphisms in the TYMS gene, as a molecule with a key
role in DNA synthesis, are associated with risk of deve-
lopment of BC as SBC and/or HBC. Although several
studies have associated this gene with other cancers
(colorectal, lung, pancreatic, gastric, and lymphoma)
[26-32], this study is the first to correlate the HBC and
SBC forms to polymorphisms in the 5’-UTR region ofin patients with breast cancer and control group
s N (%) Allelic frequencies N (%)
3R/3R 2R 3R
5 (16) 30 (48) 32 (52)
9 (24) 31 (42) 43 (58)
14 (21) 61 (45) 75 (55)
47 (36) 121 (46) 143 (54)
ast cancer; HBC = hereditary breast cancer; BC = breast cancer.
Table 2 Comparison of 2R and 3R alleles of the
polymorphism in the TYMS gene among individuals with
breast cancer and controls
Allele 2R Allele 3R χ2 p OR CI (95%)
SBC 30 32 0.05 0.82 1.11 (0.62-2.00)
Control 121 143
HBC 31 43 0.22 0.64 0.64 (0.49-1.48)
Control 121 143
BC 61 75 0.01 0.94 0.96 (0.62-1.49)
Control 121 143
χ2 = Chi-square Test Yates Corrected; OR = Odds Ratio; CI = Confidence Interval;
SBC = sporadic breast cancer; HBC = hereditary breast cancer; BC = breast
cancer.
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difficult to do association with others studies with simi-
lar characteristics.
Studies in other populations have found significative
associations between the TYMS gene 5’-UTR variations
and the BC development [2,11,12]. But the fact that the
2R/2R and 2R/3R variants (in HBC and BC/HBC/SBC,
respectively), which would have a protective effect have
presented relation, and risk effect, respectively, need to
be better studied. What can be explained by the imba-
lance of Hardy-Weinberg found, especially in our controlTable 3 Comparison of genotypic variations of the TYMS
among individuals with BC and controls
Genotypic variant of the TYMS
2R/2R 2R/3R 3R/3R
SBC 04 22 05
Control 36 49 47
χ2 2.80 10.4 3.53
p 0.11 0.001 0.06
OR 0.30 4.14 0.35
CI (95%) (0.13-1.21) (1.77-9.71) (0.12-0.97)
HBC 03 25 09
Control 36 49 47
χ2 5.94 9.68 1.9
p 0.01 0.002 0.27
OR 0.23 3.53 0.58
CI (95%) (0.06-0.81) (1.63-7.65) (0.25-1.33)
BC 07 47 14
Control 36 49 47
χ2 2.46 17.13 0.39
p 0.12 <0.001 0.53
OR 0.45 3.79 0.47
CI (95%) (0.19-1.11) (2.03-7.08) (0.24-1.52)
χ2 = Chi-square; OR = Odds Ratio; CI = Confidence Interval; In Bold = Significant
Statistical Values; SBC = sporadic breast cancer; HBC = hereditary breast cancer;
BC = breast cancer.population or by other mechanisms that need to be bet-
ter studied.
The 3R allele results in greater TYMS activity [33].
Therefore, the 2R/3R genotype should have interme-
diate activity. As the TYMS competes with MTHFR
(Methylenetetrahydrofolate reductase) at the cycle of
folic acid metabolism, the availability of 5,10-methylene
THF (tetrahydrofolate), Trinh et al. (2002) [34], issued the
hypothesis that the 3R variant could affect the levels of
5,10-methylene THF and this could lead to lower cell
concentration of S-Adenosyl methionine and consequent
decrease in DNA methylation. Thus, DNA hypomethyla-
tion, may increase susceptibility gene mutations or alter
the expression of genes as protooncogenes or tumor sup-
pressor, or would result in epigenetic changes that may
initiate carcinogenesis. The association of TYMS poly-
morphism has been reinforced in a meta-analysis, being
the 3R allele important in the BC risk [2].
The 3R/3R genotype for the TYMS gene has been
associated with high levels of enzyme activity in tumors,
and it have been considered to the best prognostic pre-
sented by chemosensibilizing (5-Flurouracil, 5-FU) to the
BC. It shows the importance of genotypic characterization
of the TYMS 5’-UTR of Brazilian population, suggesting
that genotype of TYMS gene related to the number of
repetitions in tandem can be, at least, partial indicator to
the 5-FU chemotherapy [15,35-39]. The frequency found
for triple homozygous (3R/3R), with worse prognosis, was
around 16% to 24% in our population with BC, and 36%
for the control population. The low number of individuals
with the genotype 3R/3R in our population with the
disease can be positive, due to chemotherapy efficiency
than the other two genotypes (2R/2R and 2R/3R, in more
than 75% of cases).
These observations emphasize the biological and clin-
ical importance of the TYMS polymorphisms in relation
to response and toxicity to chemotherapy [40], even more
for being related to risk of BC found in this study. Thus,
with pharmacogenomic studies it would be possible to
understand the action of different drugs in combination
with the chemotherapeutic effect and the association with
the gene analyzed, and using polymorphisms in the TYMS
gene as population biomarkers of severity to different
types of cancer, especially the BC.
In our study, the Hardy-Weinberg in control group was
not found because we selected only people without BC,
and maybe as an important factor, the natural selection
acts in the way to put better mechanisms in response to
the cancer. In other study realized in our laboratory (data
no divulgate) with an aneuploidia and controls we have
the same data, the control population (woman) not shows
Hardy-Weinberg equilibrium [63 woman; 23 (36.50%),
20 (31.75%), 20 (31.75%), respectively to 2R/2R, 2R/3R
and 3R/3R genotypes frequency, p < 0.05]. As a major
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genotype frequency without taking into account a disease
as selection factor, as we provide in the present study, as
well we include only woman (only with adult advanced
age) without BC our historical of the disease.
Conclusion
We conclude that the prevalence of allelic polymorphisms
3R (TYMS) are increased when compared with the allele
2R in our population. The identification of alleles and
genotypic variants of the promoter enhancer region
5’-UTR of the TYMS (2R and 3R) showed that the diffe-
rences found between patients with SBC and HBC are
small. The bias found in the unbalance of Hardy-Weinberg
into two groups (control and HBC) make impossible to say
that there is an association between the TYMS and the
development of breast carcinoma; but as the found results
show an association, other studies would be necessary,
increasing the number of individuals with lack of imba-
lance of constant allele frequencies found, for the same in
the control group, in order to better understand the role in
disease. But, in our data, an important aspect can be seen,
as the important of 2R/3R genotypes in the BC risk in all
groups analyzed, in this way, we need to have other studies,
in different contexts to analyze this patients, not only by
the genetic polymorphism, but including the protein
analyze.
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